The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

A NOVEL treatment approach combining daratumumab (Dara) and tocilizumab (TCZ) offers hope for patients experiencing late antibody-mediated rejection (AMR) after kidney transplantation. This ...

Health Canada's Veterinary Drugs Directorate (VDD) first looks at the drug submission to ensure it is in an acceptable format and contains sufficient information to enable a proper review. If there ...

At this stage, VDD informs CVM about the sponsor's intent to undergo a simultaneous review. The technical information about the drug product and the packages that the sponsor submits to both ...

Toripalimab was the first domestic oncology drug included in Project Orbis. Additionally, the TGA also granted an orphan drug designation to toripalimab for the treatment of NPC, which has accelerated ...

ICICI Prudential Value Discovery Fund Direct Plan Growth performance review analysis for January: ICICI Prudential Value Discovery Fund Direct Plan Growth, managed by the seasoned fund managers ...

Catch it in your inbox every Thursday. Sign-up here. Discovery Place has picked a new name and updated plans for its revamped nature museum. It’s out with Discovery Place Nature and in with ...

A rendering of the new Charlotte Museum of Nature, slated to open in spring 2026. (Courtesy of Discovery Place) Discovery Place has a name for its newly reimagined nature museum coming to south ...

Across drug discovery and development ... s mRNA-4157 in combination with Merck & Co.’s PD1-targeted monoclonal antibody pembrolizumab (Keytruda) for melanoma — an approach that could ...

This was at a lit fest in Thiruvananthapuram in early 2024. I waited keenly to read Speaking with Nature, a book described by Guha as a “group portrait” of 10 nation-shapers who were also the founding ...

I am just supposed to stop the drug for 2 months ... which is probably why my frustration and poor review of Cigna's incompetence and failure to deliver in order to save a buck.

The FDA’s approval of Amgen’s DLL3 × CD3 bispecific antibody tarlatamab (Imdelltra) last year validated the DLL3 cancer target, demonstrating its approvability in extensive-stage small-cell ...